Incretin levels in patients with hypothyroidism and the evaluation of incretin levels alterations with treatment

[1]Sinha RA, Singh BK, Yen PM. Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism. Trends Endocrinol Metab. 2014; 25:538–45.SinhaRASinghBKYenPMThyroid hormone regulation of hepatic lipid and carbohydrate metabolismTrends Endocrinol Metab2014255384510.1016/j.tem.2014.07.001Search in Google Scholar

[2]Chidakel A, Mentuccia D, Celi FS. Peripheral metabolism of thyroid hormone and glucose homeostasis. Thyroid. 2005; 15:899–903.ChidakelAMentucciaDCeliFSPeripheral metabolism of thyroid hormone and glucose homeostasisThyroid20051589990310.1089/thy.2005.15.899Search in Google Scholar

[3]Boelaert K, Franklyn JA. Thyroid hormone in health and disease. J Endocrinol. 2005; 187:1–15.BoelaertKFranklynJAThyroid hormone in health and diseaseJ Endocrinol200518711510.1677/joe.1.06131Search in Google Scholar

[4]Mastracci TL, Evans-Molina C. Pancreatic and islet development and function: the role of thyroid hormone. J Endocrinol Diabetes Obes. 2014; 2:1044.MastracciTLEvans-MolinaCPancreatic and islet development and function: the role of thyroid hormoneJ Endocrinol Diabetes Obes201421044Search in Google Scholar

[5]Ujwal Upadya B, Suma MN, Srinath KM, Prashant A, Doddamani P, Shilpa SV. Effect of insulin resistance in assessing the clinical outcome of clinical and subclinical hypothyroid patients. J Clin Diagn Res. 2015; 9:OC01–4.UjwalUpadya BSumaMNSrinathKMPrashantADoddamaniPShilpaSVEffect of insulin resistance in assessing the clinical outcome of clinical and subclinical hypothyroid patientsJ Clin Diagn Res20159OC01–4Search in Google Scholar

[6]Peppa M, Koliaki C, Nikolopoulos P, Raptis SA. Skeletal muscle insulin resistance in endocrine disease. J Biomed Biotechnol. 2010; 2010:527850.PeppaMKoliakiCNikolopoulosPRaptisSASkeletal muscle insulin resistance in endocrine diseaseJ Biomed Biotechnol2010201052785010.1155/2010/527850Search in Google Scholar

[7]Duckworth WC. Insulin degradation: mechanisms, products, and significance. Endocr Rev. 1988; 9:319–45.DuckworthWCInsulin degradation: mechanisms, products, and significanceEndocr Rev198893194510.1210/edrv-9-3-319Search in Google Scholar

[8]Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab. 2008; 34 Suppl 2:S65–72.GautierJFChoukemSPGirardJPhysiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetesDiabetes Metab200834Suppl2S657210.1016/S1262-3636(08)73397-4Search in Google Scholar

[9]Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3:153–65.DruckerDJThe biology of incretin hormonesCell Metab200631536510.1016/j.cmet.2006.01.004Search in Google Scholar

[10]Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986; 63:492–8.NauckMAHombergerESiegelEGAllenRCEatonRPEbertRCreutzfeldtWIncretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responsesJ Clin Endocrinol Metab198663492810.1210/jcem-63-2-492Search in Google Scholar

[11]Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005; 31(3 Pt 1): 233–42.GautierJFFetitaSSobngwiESalaün-MartinCBiological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetesDiabetes Metab2005313 Pt 12334210.1016/S1262-3636(07)70190-8Search in Google Scholar

[12]Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000; 141:4600–5.PerfettiRZhouJDoyleMEEganJMGlucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant ratsEndocrinology20001414600510.1210/endo.141.12.780611108273Search in Google Scholar

[13]Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003; 17:161–71.DruckerDJGlucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosisMol Endocrinol2003171617110.1210/me.2002-0306Search in Google Scholar

[14]Perros P, McCrimmon RJ, Shaw G, Frier BM. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet Med. 1995; 12:622–7.PerrosPMcCrimmonRJShawGFrierBMFrequency of thyroid dysfunction in diabetic patients: value of annual screeningDiabet Med199512622710.1111/j.1464-5491.1995.tb00553.xSearch in Google Scholar

[15]Crunkhorn S, Patti ME. Links between thyroid hormone action, oxidative metabolism, and diabetes risk? Thyroid. 2008; 18:227–37.CrunkhornSPattiMELinks between thyroid hormone action, oxidative metabolism, and diabetes risk?Thyroid2008182273710.1089/thy.2007.0249Search in Google Scholar

[16]Doong ML, Wang JW, Chung SC, Liu JY, Hwang C, Hwang CY, et al. Regulation of thyroid hormones in the secretion of insulin and gastric inhibitory polypeptide in male rats. Metabolism. 1997; 46:154–8.DoongMLWangJWChungSCLiuJYHwangCHwangCYet alRegulation of thyroid hormones in the secretion of insulin and gastric inhibitory polypeptide in male ratsMetabolism199746154810.1016/S0026-0495(97)90294-8Search in Google Scholar

[17]Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008; 294:E15–26.MuniyappaRLeeSChenHQuonMJCurrent approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usageAm J Physiol Endocrinol Metab2008294E152610.1152/ajpendo.00645.200717957034Search in Google Scholar

[18]Brenta G. Why can insulin resistance be a natural consequence of thyroid dysfunction? J Thyroid Res. 2011; 2011:152850.BrentaGWhy can insulin resistance be a natural consequence of thyroid dysfunction?J Thyroid Res2011201115285010.4061/2011/152850317569621941681Search in Google Scholar

[19]Dimitriadis GD, Leighton B, Parry-Billings M, West D, Newsholme EA. Effects of hypothyroidism on the sensitivity of glycolysis and glycogen synthesis to insulin in the soleus muscle of the rat. Biochem J. 1989; 257:369–73.DimitriadisGDLeightonBParry-BillingsMWestDNewsholmeEAEffects of hypothyroidism on the sensitivity of glycolysis and glycogen synthesis to insulin in the soleus muscle of the ratBiochem J19892573697310.1042/bj257036911355892649073Search in Google Scholar

[20]Rochon C, Tauveron I, Dejax C, Benoit P, Capitan P, Fabricio A, et al. Response of glucose disposal to hyperinsulinaemia in human hypothyroidism and hyperthyroidism. Clin Sci (Lond). 2003; 104:7–15.RochonCTauveronIDejaxCBenoitPCapitanPFabricioAet alResponse of glucose disposal to hyperinsulinaemia in human hypothyroidism and hyperthyroidismClin Sci (Lond)200310471510.1042/CS20020154Search in Google Scholar

[21]Stanicka S, Vondra K, Pelikánová T, Vlcek P, Hill M, Zamrazil V. Insulin sensitivity and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement therapy. Clin Chem Lab Med. 2005; 43:715–20.StanickaSVondraKPelikánováTVlcekPHillMZamrazilVInsulin sensitivity and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement therapyClin Chem Lab Med2005437152010.1515/CCLM.2005.12116207130Search in Google Scholar

[22]Dimitriadis G, Mitrou P, Lambadiari V, Boutati E, Maratou E, Panagiotakos DB, et al. Insulin action in adipose tissue and muscle in hypothyroidism. J Clin Endocrinol Metab. 2006; 91:4930–7.DimitriadisGMitrouPLambadiariVBoutatiEMaratouEPanagiotakosDBet alInsulin action in adipose tissue and muscle in hypothyroidismJ Clin Endocrinol Metab2006914930710.1210/jc.2006-047817003097Search in Google Scholar

[23]Maratou E, Hadjidakis DJ, Kollias A, Tsegka K, Peppa M, Alevizaki M, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol. 2009; 160:785–90.MaratouEHadjidakisDJKolliasATsegkaKPeppaMAlevizakiMet alStudies of insulin resistance in patients with clinical and subclinical hypothyroidismEur J Endocrinol20091607859010.1530/EJE-08-079719141606Search in Google Scholar

[24]Gimenez-Palop O, Giménez-Pérez G, Mauricio D, Berlanga E, Potau N, Vilardell C, et al. Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changes. Eur J Endocrinol. 2005; 153:73–9.Gimenez-PalopOGiménez-PérezGMauricioDBerlangaEPotauNVilardellCet alCirculating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changesEur J Endocrinol200515373910.1530/eje.1.0193415994748Search in Google Scholar

[25]Singh BM, Goswami B, Mallika V. Association between insulin resistance and hypothyroidism in females attending a tertiary care hospital. Indian J Clin Biochem. 2010; 25:141–5.SinghBMGoswamiBMallikaVAssociation between insulin resistance and hypothyroidism in females attending a tertiary care hospitalIndian J Clin Biochem201025141510.1007/s12291-010-0026-x345309723105900Search in Google Scholar

[26]Nada AM. Effect of treatment of overt hypothyroidism on insulin resistance. World J Diabetes. 2013; 4:157–61.NadaAMEffect of treatment of overt hypothyroidism on insulin resistanceWorld J Diabetes201341576110.4239/wjd.v4.i4.157374608923961327Search in Google Scholar

[27]Krassas GE, Pontikides N, Loustis K, Koliakos G, Constantinidis T, Kaltsas T. Resistin levels are normal in hypothyroidism and remain unchanged after attainment of euthyroidism: relationship with insulin levels and anthropometric parameters. J Endocrinol Invest. 2006; 29:606–12.KrassasGEPontikidesNLoustisKKoliakosGConstantinidisTKaltsasTResistin levels are normal in hypothyroidism and remain unchanged after attainment of euthyroidism: relationship with insulin levels and anthropometric parametersJ Endocrinol Invest2006296061210.1007/BF0334415916957408Search in Google Scholar

[28]Shah JH, Motto GS, Papagiannes E, Williams GA. Insulin metabolism in hypothyroidism. Diabetes. 1975; 24:922–5.ShahJHMottoGSPapagiannesEWilliamsGAInsulin metabolism in hypothyroidismDiabetes197524922510.2337/diab.24.10.9221175861Search in Google Scholar

[29]Handisurya A, Pacini G, Tura A, Gessl A, Kautzky-Willer A. Effects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH). Clin Endocrinol (Oxf). 2008; 69:963–9.HandisuryaAPaciniGTuraAGesslAKautzky-WillerAEffects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH)Clin Endocrinol (Oxf)200869963910.1111/j.1365-2265.2008.03280.x18429948Search in Google Scholar

[30]Hays JH, Silverman E, Potter BB, Shakir KM. Normal gastric inhibitory polypeptide response to oral glucose in hypothyroidism. J Endocrinol. 1994; 140:309–12.HaysJHSilvermanEPotterBBShakirKMNormal gastric inhibitory polypeptide response to oral glucose in hypothyroidismJ Endocrinol19941403091210.1677/joe.0.14003098169563Search in Google Scholar